Pure Global

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity - Trial NCT06373146

Access comprehensive clinical trial information for NCT06373146 through Pure Global AI's free database. This Phase 2 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 360 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06373146
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06373146
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Study Focus

Obesity

Tirzepatide

Interventional

drug

Sponsor & Location

Eli Lilly and Company

Gardena,Irvine,Los Angeles,North Hollywood,Panorama City,Santa Ana,Walnut Creek,Meridian,Marrero,Metairie,Norfolk,Fargo,Corpus Christi,Dallas,Bellevue,Mexicali,Mexico City,Monterrey,Merida,Chihuahua, Mexico,United States of America

Timeline & Enrollment

Phase 2

May 01, 2024

Apr 01, 2026

360 participants

Primary Outcome

Mean Percent Change from Baseline in Body Weight

Summary

The main purpose of this study is to determine if combining tirzepatide with the mibavademab
 will result in more weight loss in adult participants than tirzepatide alone. The study will
 last about 72 weeks and may include up to 19 visits.

ICD-10 Classifications

Obesity
Other obesity
Obesity, unspecified
Obesity due to excess calories
Obesity and other hyperalimentation

Data Source

ClinicalTrials.gov

NCT06373146

Non-Device Trial